Compare Dover Corp (DOV) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dover Corp vs Recursion Pharmaceuticals Inc — how do they compare? Dover Corp trades at $211.62 (market cap $28.84B), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.78B). The key difference: Dover Corp is far larger — about 16.2× Recursion Pharmaceuticals Inc's market cap, and Dover Corp pays a 0.97% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| DOV | RXRX | |
|---|---|---|
Market Cap | $28.84B | $1.78B |
Sector | Industrials | Health |
52-Week High | $233.31 | $6.79 |
52-Week Low | $161.16 | $2.84 |
Enterprise Value | $30.49B | $1.19B |
Dividend Yield | 0.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dover Corporation (DOV) trades at $214.27, down 0.49% on the day, with a bearish technical signal and neutral oscillators. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS expected at $2.72. Financials show solid profitability with a 13.3% net income margin and 15.06% ROE, though cash flow turned negative in 2025. Recent news highlights product launches in fueling solutions and data center technologies, indicating ongoing innovation.
The outlook is mixed: strong analyst consensus (64% buy ratings) and a $250.67 price target suggest upside, but bearish technicals and negative net cash flow pose near-term risks. Investors should weigh robust fundamentals against market volatility and execution challenges in a competitive industrial sector.
RXRX trades at $3.30, down 7.3% today, with bearish technical signals from moving averages and oscillators. The clinical-stage biotech shows severe financial strain with a -851.51% net income margin and negative cash flow from operations of -$372M in 2025, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights AI-driven drug discovery potential but questions commercial viability.
Despite analyst consensus price target of $7.83 suggesting 137% upside, high cash burn and unproven business model pose substantial risk. Investment appeal hinges on successful drug development milestones, but current fundamentals indicate speculative positioning suitable only for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
